Lyme disease, discovered in 1977, has emerged as a significant concern for both ecologists and the public. The bacterial infection, primarily spread by Borrelia burgdorferi (occasionally Borrelia mayonii) through infected Ixodes scapularis ticks on the eastern coast of the United States, leads to over 400,000 annual cases within the United States, and is often misdiagnosed. Lyme disease in humans is difficult to detect, due to its discreet host and rapid spread. It commonly initiates as a rash, pain, fatigue, and progresses to severe issues if untreated. Through our research, we aim to develop a safe, effective vaccine using outer membrane vesicles (OMVs), avoiding previous pitfalls of traditional weakened bacteria-based vaccines and triggering protective immune responses. Our goal was to produce our B. burgdorferi outer membrane protein of choice, BB0405, to be used as our future vaccine antigen. BB0405 is exceptionally unique in that it is always present during bacterial insertion into human cells, making it a perfect antigen to prevent infection. Our findings suggest that the protein is being cleaved upon production, an unexpected result that will require further examination.